Silence Therapeutics GmbH
Clinical-stage biotechnology company developing siRNA therapeutics. Uses a proprietary siRNA design platform and chemically modified, ligand-conjugated oligonucleotides to achieve targeted delivery to hepatocytes. Advances programs through preclinical candidate selection and early-phase clinical trials in cardiovascular, hematology and selected rare diseases. Maintains an intellectual property portfolio and engages external partners, patient groups and investors to support discovery, development and disclosure.
Industries
Nr. of Employees
medium (51-250)
Silence Therapeutics GmbH
United Kingdom: 12 Hammersmith Grove, London, W6 7AP; United States: 221 River Street, 9th Floor, Hoboken, NJ 07030; Germany: Robert-Rossle-Str. 10, D-13125 Berlin
Patents
Nucleic acids for inhibiting expression of a target gene comprising phosphorodithioate linkages
US-11873489-B2
View Details
Nucleic acids for inhibiting expression of a target gene comprising phosphorodithioate linkages
US-11873489-B2
View DetailsProducts
Investigational siRNA therapeutics (clinical-stage programs)
Clinical-stage siRNA development programs designed to modulate disease-relevant genes and advance candidates through early-phase clinical evaluation for genetically mediated cardiovascular, hematologic and rare diseases.
Investigational siRNA therapeutics (clinical-stage programs)
Clinical-stage siRNA development programs designed to modulate disease-relevant genes and advance candidates through early-phase clinical evaluation for genetically mediated cardiovascular, hematologic and rare diseases.
Services
Scientific and development partnerships to access external research, accelerate discovery and develop therapeutic candidates; flexible transaction models and ongoing alliance management.
Development and distribution of disease-specific educational materials, downloadable eBooks and videos to support patients, caregivers and advocacy groups.
Scientific and development partnerships to access external research, accelerate discovery and develop therapeutic candidates; flexible transaction models and ongoing alliance management.
Development and distribution of disease-specific educational materials, downloadable eBooks and videos to support patients, caregivers and advocacy groups.
Expertise Areas
- RNA interference therapeutics development
- Oligonucleotide chemistry and conjugation
- Liver-targeted drug delivery
- Preclinical pharmacology and in vivo modeling
Key Technologies
- RNA interference (RNAi)
- siRNA sequence optimization and chemical modification
- Ligand-conjugated oligonucleotides
- Linker chemistry for bioconjugation
News & Updates
Company participation in investor conference and fireside chat; webcast available.
Corporate presentation summarising pipeline, platform toolbox and clinical program highlights (November 2025).
Presentation of additional Phase 1 data for an investigational siRNA in polycythemia vera, highlighting reductions in hematocrit and tolerability (presented June 2025).
Announcement of completed enrollment in the SANRECO Phase 2 study of an investigational siRNA for polycythemia vera.
Certification badges displayed for multiple regions demonstrating internal employee-survey based recognition.
Company participation in investor conference and fireside chat; webcast available.
Corporate presentation summarising pipeline, platform toolbox and clinical program highlights (November 2025).
Presentation of additional Phase 1 data for an investigational siRNA in polycythemia vera, highlighting reductions in hematocrit and tolerability (presented June 2025).
Announcement of completed enrollment in the SANRECO Phase 2 study of an investigational siRNA for polycythemia vera.
Certification badges displayed for multiple regions demonstrating internal employee-survey based recognition.